Profile
| Metric | Value |
|---|---|
| Full Name | BeOne Medicines Ltd. |
| Ticker | NASDAQ: ONC |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Switzerland |
| IPO | |
| Indexes | Not included |
| Website | beonemedicines.com |
| Employees | 11,000 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $346.75 | |
| Price, 1D Change | -1.23% | |
| Market Cap | $38B | |
| - | ||
| PE Ratio | 667.21 | |
| Beta | 0.49 | |
| Revenue | $4B | |
| Revenue, 1Y Change | +55.04% | |
| EPS | -$6.13 | |
| EPS, 1Y Change | +27.46% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | BGNE | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$6.13 | |
| EPS Estimate | $3.41 | |
| EPS Est. Change | +155.70% | |
| Revenue | $3.81B | |
| Revenue Estimate | $5.29B | |
| Revenue Est. Change | +38.83% | |
| Current Price | $346.75 | |
| Price Target | - | $400.00 |
| Price Tgt. Change | - | +15.36% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$5.69 | -$6.13 | -7.72% | |
| $3.41 | N/A | +155.70% | |
| $6.34 | N/A | +203.51% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.71B | $3.81B | +2.76% | |
| $5.29B | N/A | +38.83% | |
| $6.42B | N/A | +68.48% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +72.52% | |
| Price, 3Y | +28.11% | |
| Market Cap, 1Y | +79.14% | |
| Market Cap, 3Y | +35.90% | |
| Revenue, 1Y | +55.04% | |
| Revenue, 3Y | +223.65% | |
| EPS, 1Y | +27.46% | |
| EPS, 3Y | +61.05% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $346.75 | |
| SMA 200 | $294.18 | |
| SMA 200 vs Price | -15.16% | |
| SMA 50 | $329.48 | |
| SMA 50 vs Price | -4.98% | |
| Beta | 0.49 | |
| ATR | $11.88 | |
| 14-Day RSI | 61.78 | |
| 10-Day Volatility | 50.06% | |
| 1-Year Volatility | 47.25% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $3.81B | |
| EPS | -$6.13 | |
| Gross Profit | $3.09B | |
| Gross Margin | 81.15% | |
| Operating Profit | -$568.20M | |
| Operating Margin | -14.91% | |
| Net Income | -$645.11M | |
| Net Margin | -16.92% | |
| EBITDA | -$396.44M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.31 | |
| Current Ratio | 1.80 | |
| Quick Ratio | 1.58 | |
| Interest Coverage | - | |
| F-Score | 7 | |
| Altman Z-Score | 7.64 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 667.21 | |
| PS Ratio | 7.71 | |
| PB Ratio | 10.10 | |
| EV/EBITDA | 106.61 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $3.33B | |
| Cash & Equivalents | $2.63B | |
| Total Assets | $5.93B | |
| Current Assets | $3.99B | |
| Total Liabilities | $2.56B | |
| Current Liabilities | $2.21B | |
| Total Debt | $1.08B | |
| Short Term Debt | $869.11M | |
| Accounts Payable | $405.00M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $4.38B | |
| Operating Expenses | $3.78B | |
| Cost Of Goods Sold | $718.78M | |
| SG&A | $1.83B | |
| D&A | $171.76M | |
| Interest Expense | $0.00 | |
| Income Tax | $111.84M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$140.63M | |
| CFI | -$548.35M | |
| CFF | $193.45M | |
| Capex | $529.14M | |
| Free Cash Flow | -$669.77M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Truist Securities | ||
| RBC Capital | → | |
| Citigroup | → | |
| RBC Capital | → | |
| Citizens | → | |
| Morgan Stanley | → | |
| JP Morgan | → | |
| Barclays | ||
| RBC Capital | → | |
| Guggenheim | → |
Analyst sentiment
Institutional ownership
Screeners with ONC
Data Sources & References
- ONC Official Website beonemedicines.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1651308/000162828025049824/0001628280-25-049824-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1651308/000165130825000031/0001651308-25-000031-index.htm
- ONC Profile on Yahoo Finance finance.yahoo.com/quote/ONC
- ONC Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/onc
FAQ
What is the ticker symbol for BeOne Medicines Ltd.?
The ticker symbol for BeOne Medicines Ltd. is NASDAQ:ONC
Does BeOne Medicines Ltd. pay dividends?
No, BeOne Medicines Ltd. does not pay dividends
What sector is BeOne Medicines Ltd. in?
BeOne Medicines Ltd. is in the Healthcare sector
What industry is BeOne Medicines Ltd. in?
BeOne Medicines Ltd. is in the Biotechnology industry
What country is BeOne Medicines Ltd. based in?
BeOne Medicines Ltd. is headquartered in Switzerland
When did BeOne Medicines Ltd. go public?
BeOne Medicines Ltd. initial public offering (IPO) was on February 2, 2016
Is BeOne Medicines Ltd. in the S&P 500?
No, BeOne Medicines Ltd. is not included in the S&P 500 index
Is BeOne Medicines Ltd. in the NASDAQ 100?
No, BeOne Medicines Ltd. is not included in the NASDAQ 100 index
Is BeOne Medicines Ltd. in the Dow Jones?
No, BeOne Medicines Ltd. is not included in the Dow Jones index
When was BeOne Medicines Ltd. last earnings report?
BeOne Medicines Ltd.'s most recent earnings report was on November 6, 2025
When does BeOne Medicines Ltd. report earnings?
The next expected earnings date for BeOne Medicines Ltd. is February 26, 2026